VILNIAUS UNIVERSITETAS

Doudna and Charpentier's lawyers seek to revoke their European CRISPR–Cas9 patents after an unfavorable EPO opinion, citing procedural strategy rather than conceding patent invalidity, while maintaining broader patent protection in Europe and the US.

Darolutamide plus androgen-deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) by 46% versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups and a favorable safety profile.